AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11179154
Drug: Minimum intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minimum intervention group (no further treatment).
Trial: 8118539
Drug: Albuterol treatment
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol treatment (two puffs from a metered-dose inhaler with spacer at 20-minute intervals)
Trial: 8118539
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (two puffs from a metered-dose inhaler with spacer at 20-minute intervals)
Trial: 24299257
Drug: Early physical
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early physical therapy intervention (ePT) consisting primarily of manual therapy, exercise, and modalities.
Trial: 24299257
Drug: Usual podiatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual podiatric care (uPOD) consisting primarily of a stretching handout, medication, injections, and orthotics.
Trial: 24299257
Drug: Early physical
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early physical therapy intervention (ePT)
Trial: 12850362
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B streptococcal type III CPS-TT conjugate vaccine
Trial: 10717782
Drug: One implant
RxNorm normalized name: Testosterone Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One implant of MENT acetate
Trial: 10717782
Drug: Two implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two implants of MENT acetate
Trial: 10717782
Drug: Four implants
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four implants of MENT acetate
Trial: 1718693
Drug: Gallopamil (50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil (50mg 3 times daily)
Trial: 1718693
Drug: Nifedipine (20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20mg 3 times daily)
Trial: 1718693
Drug: Gallopamil (100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil (100mg twice daily)
Trial: 1718693
Drug: Nifedipine (20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20mg twice daily)
Trial: 6152885
Drug: Intercostal nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intercostal nerve blockades (ICB) with 18-28 ml of plain bupivacaine 0.5% (1.30-1.82 mg kg-1)
Trial: 29979283
Drug: Agonist-Antagonist Paired
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agonist-Antagonist Paired Set (PS)
Trial: 21270204
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of PFF with insulin sensitivity and β-cell function
Trial: 14979610
Drug: MLBL (immunostimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLBL (immunostimulating therapy) - one sublingual tablet per day for 10 consecutive days per month for 3 months
Trial: 14979610
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - one sublingual tablet of taste masked placebo per day for 10 consecutive days per month for 3 months
Trial: 3089941
Drug: Phenoxymethylpenicillin 2
RxNorm normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenoxymethylpenicillin 2 g b.i.d. for ten days
Trial: 3089941
Drug: Phenoxymethylpenicillin 2
RxNorm normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenoxymethylpenicillin 2 g b.i.d. and metronidazole 0.8 g b.i.d. for ten days
Trial: 20718183
Drug: Glutamine supplementation
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine supplementation (0.3 g/kg/day for seven days)
Trial: 14636103
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate supplementation (30 g/day for the first 2 weeks, 15 g/day for the final 2 weeks)
Trial: 11276624
Drug: High-dose IFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IFN alpha-2b
Trial: 11276624
Drug: Low-dose IFN
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IFN alpha-2b
Trial: 6404192
Drug: DSCG (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSCG (20 mg)
Trial: 28710229
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of antibiotic therapy
Trial: 28768848
Drug: Antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy (specific agents not detailed, but includes aspirin-clopidogrel)
Trial: 25111348
Drug: Multisource phase-controlled
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multisource phase-controlled radiofrequency (MPCRF) treatment on the treated side of the face
Trial: 15031778
Drug: pioglitazone 45
RxNorm normalized name: pioglitazone 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pioglitazone 45 mg once daily
Trial: 15031778
Drug: acarbose 300
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: acarbose 300 mg/day (3 equal doses)
Trial: 10450615
Drug: Supportive psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive psychotherapy (SPT) plus antidepressant medication
Trial: 10450615
Drug: Medication-alone condition
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-alone condition
Trial: 2232453
Drug: Hydrochlorothiazide (HCT)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCT) + potassium-sparing diuretics (double doses)
Trial: 28349578
Drug: Clinical pharmacist
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pharmacist intervention providing pharmaceutical care services and close collaboration with physicians.
Trial: 27604812
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and parenteral antibiotics
Trial: 27604812
Drug: Rectal surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal surgery
Trial: 21950458
Drug: Carbamazepine (100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (100mg three times daily for 7 days)
Trial: 11476257
Drug: Heroin (2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heroin (2% solution)
Trial: 11476257
Drug: Morphine (3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (3% solution)
Trial: 9609749
Drug: ISIS 2302
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS 2302 (0.5, 1, or 2 mg/kg)
Trial: 2457072
Drug: Microsphere pancreatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microsphere pancreatic enzyme preparations (Pancrease, Creon)
Trial: 2457072
Drug: Conventional enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional enzyme preparation (Pancrex V Forte)
Trial: 2457072
Drug: Microsphere pancreatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microsphere pancreatic enzyme preparations (Pancrease, Creon, pancreatin Merck)
Trial: 2457072
Drug: Microsphere pancreatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microsphere pancreatic enzyme preparations (Creon)
Trial: 201592
Drug: Steroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid therapy after clinical deterioration
Trial: 27056686
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) × 2 doses
Trial: 27056686
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HA) single dose
Trial: 27056686
Drug: Ozone ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone × 4 doses
Trial: 25543089
Drug: Interferon beta-1b
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1b (IFNβ) treatment
Trial: 21859185
Drug: CBT +
RxNorm normalized name: Cannabidiol
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CBT + BWL (sequential treatment)
Trial: 16702981
Drug: Amlodipine (A)
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine (A) + Lisinopril (L)
Trial: 15084389
Drug: Cisplatin +
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin + vinorelbine 25 mg/m2 days 1, 8 and 15
Trial: 15084389
Drug: Cisplatin +
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin + gemcitabine 1000 mg/m2 days 1, 8 and 15
Trial: 15084389
Drug: Cisplatin +
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin + paclitaxel 200 mg/m2 day 1 iv over 1h
Trial: 15084389
Drug: Cisplatin +
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin + etoposide 100 mg/m2 po days 1-6
Trial: 7889961
Drug: Cefprozil, given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefprozil, given once or twice daily
Trial: 7889961
Drug: Cefaclor, amoxicillin‐clavulanate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor, amoxicillin‐clavulanate, or erythromycin
Trial: 2606428
Drug: Colchicine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 1.0 mg
Trial: 2606428
Drug: Colchicine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 1.5 mg
Trial: 26115189
Drug: Continuous adductor
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous adductor canal block (2‐day ropivacaine 0.2% infusion)
Trial: 26115189
Drug: Continuous femoral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous femoral nerve block (2‐day ropivacaine 0.2% infusion)
Trial: 16953000
Drug: Tryptophan depletion
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tryptophan depletion (TD) induced by administration of capsules containing an amino acid mixture without tryptophan.
Trial: 16953000
Drug: Sham depletion
RxNorm normalized name: Allogeneic thymocyte-depleted thymus tissue-agdc
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham depletion using identical capsules containing lactose.
Trial: 15575909
Drug: Alfacalcidol 0.25
RxNorm normalized name: alfacalcidol 0.25 MCG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol 0.25 microg daily
Trial: 11685731
Drug: Docetaxel alone
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel alone (30 mg/m² intravenously, every 7 days for 3 weeks)
Trial: 11685731
Drug: Docetaxel plus
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel plus thalidomide (200 mg at bedtime)
Trial: 7947128
Drug: Personal medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal medication record card
Trial: 3283061
Drug: Nicardipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (30 mg, three times a day)
Trial: 3283061
Drug: Verapamil (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (120 mg, three times a day)
Trial: 24215485
Drug: Fixed-dose ZDV/3TC/abacavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose ZDV/3TC/abacavir (TZV)
Trial: 20435936
Drug: Midazolam (0.035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.035 to 0.05 mg x kg(‐1) IV for 1 minute followed by an infusion of 0.035 to 0.05 mg x kg(‐1) x h(‐1) for 59 minutes)
Trial: 20435936
Drug: Midazolam with
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam with propofol (target‐controlled infusion of propofol at constant C(T): 0.6 or 1.0 microg x mL(‐1))
Trial: 20435936
Drug: Propofol (C(blood):
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (C(blood): 1.2 microg x mL(‐1))
Trial: 18306161
Drug: LED treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LED treatments (660 nm)
Trial: 16754269
Drug: Candesartan 8‐16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 8‐16 mg daily
Trial: 10069091
Drug: Hypnotic intervention
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic intervention (individual sessions, audiotapes) designed to augment fracture healing.
Trial: 8850384
Drug: Intravenous dopexamine
RxNorm normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dopexamine at a rate of 0.5 micrograms/kg/min, titrated to achieve a 30% or more increase in cardiac index
Trial: 2209343
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of glipizide (20 mg before breakfast and dinner) and human proinsulin (subcutaneously at bedtime)
Trial: 2209343
Drug: Glipizide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide (20 mg before breakfast and dinner) and human proinsulin placebo
Trial: 7243605
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg peptide analog of ACTH/MSH 4-9
Trial: 7243605
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg peptide analog of ACTH/MSH 4-9
Trial: 7243605
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg peptide analog of ACTH/MSH 4-9
Trial: 7243605
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg peptide analog of ACTH/MSH 4-9 (placebo)
Trial: 7243605
Drug: peptide analog
RxNorm normalized name: Re188 P2045 somatostatin peptide analogue
DrugBank: P-2045 Re-188 (DB17204)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peptide analog of ACTH/MSH 4-9 (all doses)
Trial: 31605549
Drug: COMDQ-15 (short
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMDQ-15 (short version of the Chronic Oral Mucosal Disease Questionnaire)
Trial: 27545448
Drug: Fondaparinux 2.5
RxNorm normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux 2.5 mg once daily until postoperative day 5
Trial: 27545448
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin 2000 units twice daily until postoperative day 5
Trial: 18211609
Drug: Topical antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antioxidant treatment with vitamin C and alpha-glucosylrutin
Trial: 15926437
Drug: Topical fluoride
RxNorm normalized name: Carles 60 Second APF 1.23% Topical Fluoride Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluoride gel applied prior to acid etching (test group)
Trial: 15926437
Drug: Fissure sealant
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fissure sealant applied without prior fluoride treatment (control group)
Trial: 12800810
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and moxibustion treatment for six sessions over a 3-week period
Trial: 10479134
Drug: MN rgp120
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MN rgp120 vaccine
Trial: 8759414
Drug: Hydrochlorothiazide (HTZ:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HTZ: 25 mg o.d.)
Trial: 8759414
Drug: Propranolol (PRO:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (PRO: 40 mg t.i.d.)
Trial: 2862619
Drug: Corynanthine 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corynanthine 2% (applied two or three times daily for one, two, or three weeks)
Trial: 27306792
Drug: OTL38 (near-infrared
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTL38 (near-infrared fluorescent agent) administered intravenously in increasing doses.
Trial: 27306792
Drug: OTL38 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTL38 administered intravenously to patients with ovarian cancer.
Trial: 24926548
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m intravenous every 21 days) with PX-866 (8 mg orally daily)
Trial: 24926548
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m intravenous every 21 days) without PX-866
Trial: 22814125
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (CT) (n=85)
Trial: 22814125
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (CT) (n=91)
Trial: 15050905
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) for 2-3 years
Trial: 12202466
Drug: Risedronate (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (2.5 mg or more)
Trial: 11317832
Drug: Tamsulosin 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.8 mg daily
Trial: 9789483
Drug: Tamsulosin (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (any dose)
Trial: 7502628
Drug: Hydroxyurea (HU)
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (HU) for up to 12 months followed by combination therapy with HU and human recombinant erythropoietin (rHuEpo; 400 U/kg/week i.v.) for 3-4 weeks.
Trial: 7502628
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with HU and rHuEpo
Trial: 7046777
Drug: Xipamide 10
RxNorm normalized name: xipamide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xipamide 10 mg daily
Trial: 7046777
Drug: Xipamide 20
RxNorm normalized name: xipamide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xipamide 20 mg daily
Trial: 7046777
Drug: Cyclopenthiazide 0.5
RxNorm normalized name: cyclopenthiazide 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclopenthiazide 0.5 mg daily
Trial: 20004779
Drug: Early therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early therapy with inhaled corticosteroid (ICS) budesonide for 2 years
Trial: 20004779
Drug: Delayed therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed therapy with inhaled corticosteroid (ICS) budesonide after 2 years of terbutaline treatment
Trial: 17312235
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ropivacaine and clonidine (block group)
Trial: 15257093
Drug: L‐NAME treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NAME treatment
Trial: 7946580
Drug: Information on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information on proposed treatment arm only
Trial: 1762806
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of epidural morphine
Trial: 1762806
Drug: Repeated bolus
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated bolus doses of epidural morphine
Trial: 26427111
Drug: Votalin, 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Votalin, 75 mg, once a day for 8 weeks
Trial: 19009458
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day of vitamin C for 14 days
Trial: 19009458
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg ascorbate after a 7-14 day non-intervention period
Trial: 19009458
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg ascorbate dosage regimen
Trial: 19009458
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg ascorbate dosage regimen
Trial: 19009458
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg ascorbate dosage regimen